Special features of NSAID intolerance in children;Particularidades de la intolerancia AINEs en niños

Allergologia et Immunopathologia

Volumn 31, Issue 3, 2003, Pages 109-125

  Porto Arceo, J A ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Acetylsalicylic acid; Adverse drug reactions; ASA; Aspirin; Non steroidal anti inflammatory drugs; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; FENOPROFEN; FLURBIPROFEN; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYSOSOME ENZYME; MECLOFENAMIC ACID; MEFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PARACETAMOL; PIROXICAM; PROSTAGLANDIN E2; SALICYLIC ACID DERIVATIVE; SALSALATE; SULINDAC; TARTRAZINE; TOLMETIN; UNINDEXED DRUG;

ALLERGIC URTICARIA; ARTHROPATHY; ASEPTIC MENINGITIS; ASTHMA; BLOOD DYSCRASIA; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CROSS REACTION; CYTOTOXIC LYMPHOCYTE; DESENSITIZATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEVER; HEARING IMPAIRMENT; HEARTBURN; HUMAN; HYPOTHESIS; INFLAMMATION; LIVER TOXICITY; NEPHROTOXICITY; NOSE POLYP; PATHOGENESIS; PNEUMONIA; PREVALENCE; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; STOMACH PAIN; THROMBOCYTE ACTIVATION; TINNITUS; TREATMENT INDICATION; VERTIGO; VIRUS INFECTION; VOMITING;

EID: 0037528185     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0546(03)79277-5     Document Type: Conference Paper

References (110)

1. Alberdi J, Muñoz-López F. Intolerancia al Acido acetil salicílico en niños. Arch. Pediat 1988;39:371-8.
2. Giraldo B, Blumenthal MN, Spink WW. Aspirin intolerance and asthma. A clinical and immunological study. Ann. Inter Med 1969;71:479-96.
3. Chaffe FH, Settipane GA. Aspirin intolerance. Frequency in an allergic population. J. Allergy Clin. Immunol 1974;53:193-9 (trabajo 13-4).
4. Castillo JA, Picado C. Prevalence of aspirin intolerance in asthmatics treated in a hospital. Respiration 1986;50:153-7.
5. Stevenson D. Allergy and Asthma Proceedings 2002;XIV(4):24-30.
6. Asad SI, Kemeny DM, Youlten LSF, Frankland AW, Lesoff MH. Effects of aspirin in aspirin sensitive patients. Br Med J 1984;288:745.
7. García R, et al. Estudio de las reacciones de intolerancia. Hipersensibilidad a la aspirina. XIII Congr. Nac. SEAIC. Libro de Ponencias. Ed. Abelló, 1983;290-304.
8. Minden P, Farr RS. Human antibodies against acetylsalicylic acid-altered human serum albumin. Arthritis and Rheum 1967;10:99.
9. Amos HE, Wilson DV, Tausing MJ, Carlton S. Hypersensitivity reactions to acetylsalicylic acid attached to proteins through the carboxyl group. Clin Exp Immunol 1971;8:63.
10. Phills JH, Perelmutter L. IgE mediated and non-IgE mediated allergic-type reactions to aspirin. Acta Allergol 1974;29:474.
11. DeWeck AL. Immunological effects of aspirin anhidride, a contaminant of commercial acetylsalicylic acid preparations. Int Arch Allergy 1971;41:393.
12. Weltman JK, Szaro RP, Settipane GA. Allergy 1978;34:273-81.
13. Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, Suau R. Angioedema and IgE antibodies to aspirin: a case report. Annals of Allergy 1989;62:295-8.
14. Vatanasuk M, Hornbrook M, Kohler PF. Serum IgE and passive transfer in aspirin intolerance. J Allergy 1971;47:109.
15. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67-9.
16. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
17. Hayllar J, Bjarnason I. NSAIDs, COX-2 inhibitors, and the gut. Lancet 1955;346:521-2.
18. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
19. Flower R. The roles of COX-1 and COX-2: implications for NSAID development. Curr Opin Rheumatol 1996;9:9-13.
20. Meade EA, Smith WL, De Witt DL. Differential inhibition of protaglandin endoperoxide synthase (ciclooxygenasa) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
21. Kowalski ML. Aspirin-sensitive rhinosinusitis/asthma syndrome. Pathophysiology and Management. ACI International 1996;8-2:49-56.
22. Arm JP, O'Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E-4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1987;140:149-53.
23. Morais de Almeida M, Gaspar A, Carvalho F, Nogueira J, Rosado J. Hipersensibilidade aos Anti-inflatatórios nao esteróides. Novas e velhas estratėgias. Rev Port Imunoalergol 1998;5(4):335-43.
24. Szczeklik A. The ciclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-93.
25. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-4.
26. Stevenson DD, Lewis RA. Proposed mechanism of aspirin sensitivity reactions. J Allergy Clin Immunol 1987;80:788-90.
27. Lee T.H. Mechanism of aspirin sensitivity. Am Rev Respir Dis 1992;145:34-6.
28. Schmitz-Schumann M, Menz G, Schaufele A. Evidence of PAF-lelease and platelet activation in analgesics-asthma syndrome. Agents Actions Suppl 1987;21:215-24.
29. Borgeat P, Fruteau de Laclos B, Maclouf J. New concepts in the modulation of leukotriene synthesis. Biochem Pharmacol 1983;32:381-7.
30. Nizankowska E, Michalska Z, Wandzilak M. An abnormality of arachidonic acid metabolism is not generalized phenomenon in patients with aspirin-induced asthma. Eicosanoids. 1988;1:45-8.
31. Nizankowska E, Sheridan AQ, Maile M.H, Cross CJ, Szczeklik A. Pharmacological attempts to modulate leukotriene synthesis in aspirin-induced asthma. Agents Actions Suppl. 1987;21:203-13.
32. Szceklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.
33. Lasalle P, Delneste Y, Gosset P, Grass H, Wallaert B, Tonnel AM. T and B cell immune response to a 55kDa endothelial cell -derived antigen in severe asthma. Eur J Immunol 1993;23:796-803.
34. Szczeklik A, Musial J, Pulka G. Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma. Allergy 1997;52:352-4.
35. Relman DA. The search for unrecognized pathogens. Science 1999;284:1308-12.
36. Nasser SMS, Lee TH. Leukotrienes in aspirin-sensitive asthma. In Szczeklik A (eds). Eicosanoids, Aspirine, and Asthma. New York; Marcel Dekker, Inc., 1998;317-35.
37. 4 and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
38. Sladek K, Szczeklik A. Cysteinil leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-3.
39. Ferreri NR, Howlan WC, Stevenson, Spielberg HL. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1992;14:65-9.
40. Inn KH, Asano K, Beier D, Grobholz J, et al. Naturally occurring mutation in the human 5-lioxygenase gene promoter that modify transcription factor binding and reproter gene transcription. J Clin Invest 1997;99:1130-7.
41. 4 synthetase: Organization, nucleotide sequence and chromosomal localization to 5q35. J Biol Chem 1996;271:11356-61.
42. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600.
43. Szczeklik A, Sanak M. ACI Molecular mechanisms in aspirin-induced asthma. ACI International 2000;12/4:171-6.
44. Szczeklik A, Mastalerz L, Nizankowska E, Cmial A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996;153:567-71.
45. Picado C, Fernandez C, Juan M, Roca J, Fuentes M, Xaube A. Cyclooxygenase-2 mRNA is downexpresed in nasal polyps from aspirin sensitive asthmatics. Am J Respir Crit Care Med 1999;160:291-6.
46. Kowalski ML, Pawliczak J, Wozniak K, Sluda M, Altered metabolism of arachidonic acid in nasal polyepithelial cells cultured from patients with aspirin-sensitive asthma/rhinosinusitis. Allergy 1998;53(Suppl 43):11.
47. Szczeklik A, Gryglewski RJ, Olszewski E, Dembiñska A, Czerniawska G. Aspirin-sensitive asthma: The effect of aspirin on tha release of prostaglandins from nasal polyps. Phermacol Res Commun 1997;9:415-25.
48. Estrada RJL, Florido LJF, Belchi HJ. Astha in children and ASA intolerance. J Invest Allergol Clin Immunol 1993;3:315-20.
49. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Allergy 1980;35:149-54.
50. th ed. St. Louis: Mosby, 1998;1225-34.
51. Lumry WR, Curd JG, Zieger RS, Pleskow WW, Stevenson DD. Aspirin-sensitive rhinosinusitis: The clinical syndrome and effects of aspirin administration. J Allergy Clin Immunol 1983;71:580-7.
52. Widal MF, Abramin P, Lermoyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922;30:189-92.
53. Szczeklik A, Gryglewski R, Nizankowka E. Asthma relieved by aspirin and by other cyclooxigenase inhibitors. Thorax 1978;33:664.
54. Okazaki T, et al. Regulatory role of prostaglandin E in allergic histamine release with observations on the responsiveness of basophil leukocytes and the effect of acetylsalicylic acid. J Allegy Clin Immnunol 1977;60:360.
55. Mathison DA, Stevenson DD. Hypersensivity to non-steroidal antiinflamatory drugs: Indications and methods for oral challenge. J Allergy Clin Immunol 1979;64:669-74.
56. Mathison DA, Lumry WR, Stevenson DD. Aspirin in chronic urticaria and/or angioedema: Studies of sensivity and desensitization. J Allergy Clin Immunol 1982;69:135.
57. Gerber JG, Payne NA, Oelz O, Nies AS, Oates JA. Tartrazine and the protaglandin system. J Allergy Clin Immunol 1979;63:289-94.
58. Simon RA. Adverse reactions to drug additives. J Allergy Clin Immunol 1984;74:623-30.
59. Virchow CH, Szczeklik A, Bianco S. Intolerance to tratrazine in aspirin-induced asthma: results of a multicenter study. Respiration, 1988;53:20-23.
60. Dajani BM, Sliman NA, Shubair KS, Hamzeh YS. Bronchospasm caused by intravenous hydrocortisone sodium succinate (solu-Cortef) in aspirin-sensitive asthmatics. J Allergy Clin Immunol 1981;68:201-4.
61. Szczeklik A, Nizankowska E, Czerniawska-Mysik G, Sek S. Hydrocortisone and airlow impairment in aspirin-induced asthma. J Allergy Clin Immunol 1985;76:530-6.
62. Di Rosa M, Flowre RJ, Hirata F, Parente L, Russo-Marie F. Anti-phospholipase proteins. Protaglandins 1984;28:441-2.
63. Pash JM, Bayley M. Inhibition of corticosteroids of epidermal growth factor-induced recovery of cyclooxyegenase after aspirin inactivation. FASEB J 1988;2:2613-8.
64. Taniguchi M, Sato A. Aspirin-induced asthmatics (AIA) have cross-sensitivity with the steroid succinate ester. N Engl Reg Allergy Proc. 1988;9:388 (Abstr. 358).
65. a ed. W.B. Saunders Company, 2001.
66. Rainsford KD. Aspirin and the salicylates. London: Butherworths, 1984.
67. Rosenkranz B, Fischer C, Meese CO, Froplich JC. Effects of salicylic and acteylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man. Br J Clin Pharmacol 1986;21:309-17.
68. Samter M, Beers RF. Intolerance to aspirine. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-83.
69. Bianco S, Petrigni G, Felisi E, Robuschi M. Tolerance of guaiacolic ester of acetytsalicylic acid by patients with aspirin induced asthma. Scand. J Respir Dis 1979;60:350-4.
70. Barles PG, Duce F, Portillo JR, Perez J, Escuer JL. Adverse reaction to acetaminophen as an alternative analgesic in AAS triad. Allergol et Immunopatohol (Madr), 1988;16:321-5.
71. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. revalence of cross-sensitivity with acetaminophen in aspirine-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:485.
72. Lans W. Actions of anti-inflammatory drugs. Trends Pharmacol. Sci March 1981;78-80.
73. Szczeklik A. Asma inducido por aspirina: Patogenia y manifestaciones clínicas. Allergy Proceedings 1993;VII(1):14-27.
74. Stevenson DD, Simon RA, Tathison DA. Aspirin sensitive asthma tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980;66:82.
75. Dahlen B, Zetterström O. Comparison of bronchial and peroral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J 1990;3:527-34.
76. Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF, Meyers DA, Norman PS, Lichtenstein LM. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128:587-602.
77. Picado C, Ramis I, Roselló J, Prat J, Bulbema O, Plaza V, Monserrat JM, Gelpi E. Release of peptide leukotriene into nasal secretions after local instillation of aspirine in aspirine-sensitive asthmatic patients. Am Rev Respir Dis 1992;145:65-9.
78. Tomaz E, Ferreira M, Spinola M, Oliveira M, Clode M, Palma A. Pruebas de provocación nasal en el diagnóstico de la urticaria inducida por acido acetilsalicílico. Allergy and Asthma Proceedings 1998;XII(2):36-40.
79. Nizankowska E, Sczceklik A. Glucocorticosteriods attenuate aspirin-precipitated adverse reactions in aspirin-intolerant patients with asthma. Ann Allergy 1989;63:159-62.
80. Basomba A, Romar A, Pelaez A, Villalmanzo IG, Campos A. The effect of sodium cromoglycate in preventing aspirin-induced bronchospam. Cin Allergy 1976;6:269-75.
81. Mertelli NA, Usandivaras G. Inhibition of aspirin-induced bronchoconstriction by sodium cromoglycate inhalation. Thorax 1977;32:684-90.
82. Delaney JC. The effect of ketotifen on aspirin-induced asthmatic reactions. Clin allergy 1983;13:247-51.
83. SzczeklikA, Serwinska M. inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine. Thorax 1979;34:654-7.
84. Senna GE, Passalacqua G, Andri G. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Safety 1996;14:94-103.
85. Bianco S, Robuschi M, Petrigni G. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993;46:115-20.
86. Champion RH, Roberts SOB, Carpenter RG, Roger JH. Urticaria and angio-oedema: a review of 554 patients. Br J Dermatol 1969;81:588-97.
87. Warin RP. Effect of aspirin in chronic urticaria. Br J Dermatol 1960;72:350-1.
88. Estrada JL, Florido JF, Belchi J, Martin F, Diaz JM, Garcia M, Sastra J, Ojeda A. Asthma in children and ASA intolerance. J Invest Allergol Clin Immunol 1993;3(6):315-20.
89. Abrishami MA, Thomas J. Aspirin intolerance A review. Ann Allergy 1977;39:28.
90. Tan Y, Collins-Willians C. Aspirin-induced asthma in children. Ann Allergy 1982;48(1):1-5.
91. Yunginger JW, O'Connell EJ, Logan GB. Aspirin-induced asthma in children. Pediatrics 1973;82(2):218-21.
92. Botey J, Ibero M, Malet A, Marin A, Eseverri JL. Aspirin-induced recurrent urticaria and recurrent angiedema in non-atopic children. Ann of Allergy 1984;53:265-7.
93. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976;57:440-8.
94. Stevenson DD, Hankammer MA, Tathison DA. Aspirin-sensitive asthma: Tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980;66:82-8.
95. Stevenson DD, Hankammer MA, Tathison DA. Long term ASA desentization treatment of aspirin sensitive asthmatic patients. Clinical outcome studies. J Allergy Clin Immunol 1996;98:751-8.
96. Israel E, Fischer RA, Rosemberg MA. The pivotal role of 5-lipoxygenase in tha reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
97. 4 concentrations in aspirin-sensitive asthma. Am J Resp Crit Care Med 1995;151:1326-30.
98. Enrique E, Garcia P, Gaig P, San Miguel M. Failure of montelukast to prevent anaphylaxis to diclofenac. Allergy 1999;54:529.
99. Kowalski ML, Grzegorczyk J, Wojciechowska B. Intranasal challenge with lysine-ASA induces activation of eosinophils and mast cells in ASA sensitive patients. Allergy 1993;48:187.
100. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994;48:431-54.
101. Casolaro V, Meliota S, Marino O. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mastcells. J Pharmacol Exp Ther. 1993;267:1375-85.
102. Dapino P, Ottonello L, Dallegri F. The anti-inflammatory drug nimesulide inhibits neutrophil adherence to and migration across monolayers of cytokine-activated endothelial cells. Respiration 1994;61:336-41.
103. Faria E, Tomás MR, Carrapatoso I. Intolerâcia aos antiinflamatorios nao esteróides: atitude diagnóstica e alternativa terapêutica. Via Pneumológica 1995;VIII(1-2):47-57.
104. Churchill L, Graham A, Shih CK, Pauletti D, Farina PR, Grob P. Selective Inhibition of human cycloxxygenase-2 by meloxicam. Inflammopharmacollogy 1996;4:125-35.
105. Noble S, Balfour JA. Meloxicam. Drugs 1996;51:424-30.
106. Wojtuledwsky JA, Schattemkirchener M, Barceló P. A six-month double-blin trial compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35:22-8.
107. Lindén B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;5:35-8.
108. Martin C. Inhibidores selectivos de COX-2 en el asma por AINEs. ¿seguros?. Libro de Ponencias. Debates sobre Alergologia. Formigal, febrero 2001.
109. Borges S, Capriles M, Caballero F, Perez CR. Ann Allergy Asthma Immunol 2001;87(3):201-4.
110. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108(1):47-51.